secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2023-12-13T23:59:59+00:00
Accession:  0000078003-23-000120
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer guides FY2024 rev $58.5-61.5B, adj EPS $2.05-2.25; Seagen closing Dec 14
-------------------------------------------------------------------------------

- FY2024 revenue guidance $58.5-$61.5B; includes ~$8B from Comirnaty/Paxlovid and ~$3.1B from Seagen.
- FY2024 adjusted diluted EPS guidance $2.05-$2.25; includes ~$0.40 dilution from Seagen.
- Cost realignment program now expected to deliver at least $4.0B annual net savings by end 2024.
- Excluding COVID products and Seagen, operational revenue growth 3%-5% YoY.
- Seagen acquisition has received all regulatory approvals; closing expected Dec 14, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800323000120/0000078003-23-000120-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800323000120/pfe-20231213.htm
  HTML page:      https://secwatch.observer/filing/0000078003-23-000120

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer